Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Chromocell Therapeutics Corp CHRO

Healthcare Biotechnology
Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:CHRO)

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

GlobeNewswire 9 days ago

Chromocell to Present at Upcoming Fall Investor Conferences

GlobeNewswire 10 days ago

Chromocell Announces Amendment to Stock Repurchase Plan

GlobeNewswire October 24, 2024

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Chromocell Announces Stock Repurchase Plan

GlobeNewswire August 7, 2024

Chromocell to Participate in the Virtual Investor Lunch Break Series

GlobeNewswire July 15, 2024

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

GlobeNewswire May 13, 2024

Chromocell Issues Letter to Stockholders from Chief Executive Officer

GlobeNewswire April 9, 2024

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

GlobeNewswire March 21, 2024
View More News ››

Opinion & Analysis (NYSEAM:CHRO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:CHRO)

CHRO.....On watch

Last at ~ $0.62 No position
Iseneschal - 10 days ago

Excellent interview with Chromocell CEO!

https://youtu.be/9yNGoJ873Xg?si=eJnrzmrnOLvt8Bo2
BryceCanada - March 10, 2024
View more Bullboard ››

Sparta Capital Ltd.

Sparta Capital Ltd.

Sparta Capital Ltd. is a technology-based company. The Company is focused on integrating emerging technologies. The Company ...
View More »